Literature DB >> 3311462

Human IgG subclass measurements in the clinical laboratory.

R G Hamilton1.   

Abstract

Complement activation, cell surface-receptor binding, blocking activity, and possibly placental transfer are among the biologically important functional differences that have been detected between the four human IgG subclasses by use of polyclonal antisera. In 1985, a IUIS/WHO panel of immunologists, using eight immunological methods, documented the specificity of select monoclonal antibodies for the IgG subclasses. Clinical assays have been developed involving these monoclonal antibodies that allow quantification of the concentration of IgG subclass protein and distribution of the IgG subclass antibodies in human immune responses. This review addresses issues of concern to investigators who are evaluating and (or) developing quantitative human IgG subclass assays in the clinical laboratory. Unique physical (structural) and biological (functional) properties of human IgG subclasses are summarized, with a focus on aspects pertinent to their clinical importance and in vitro quantification. The HP-series monoclonal antibodies with documented specificity are examined within the context of their application to several immunological methods. I describe unique technical aspects of total and antigen-specific IgG-subclass immunoassays involving these monoclonal antibodies. Finally, this report outlines clinical applications and indications for IgG-subclass measurements in the study of human health and disease.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3311462

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  39 in total

1.  An Extended Minimal Physiologically Based Pharmacokinetic Model: Evaluation of Type II Diabetes Mellitus and Diabetic Nephropathy on Human IgG Pharmacokinetics in Rats.

Authors:  Gurkishan S Chadha; Marilyn E Morris
Journal:  AAPS J       Date:  2015-08-15       Impact factor: 4.009

2.  Detection of Mycoplasma genitalium-reactive cervicovaginal antibodies among infected women.

Authors:  Stefanie L Iverson-Cabral; Lisa E Manhart; Patricia A Totten
Journal:  Clin Vaccine Immunol       Date:  2011-08-03

3.  Behaviour of two IgG subclasses in transport of immunoglobulin across the human placenta.

Authors:  L C Mongan; C D Ockleford
Journal:  J Anat       Date:  1996-02       Impact factor: 2.610

4.  Absolute Quantitation of Glycoforms of Two Human IgG Subclasses Using Synthetic Fc Peptides and Glycopeptides.

Authors:  Rini Roy; Evelyn Ang; Emy Komatsu; Ronald Domalaon; Adrien Bosseboeuf; Jean Harb; Sylvie Hermouet; Oleg Krokhin; Frank Schweizer; Hélène Perreault
Journal:  J Am Soc Mass Spectrom       Date:  2018-05-23       Impact factor: 3.109

5.  Immunological features and functional analysis of anti-CFH autoantibodies in patients with atypical hemolytic uremic syndrome.

Authors:  Wei-Yi Guo; Di Song; Xiao-Rong Liu; Zhi Chen; Hui-Jie Xiao; Jie Ding; Shu-Zhen Sun; Hong-Yan Liu; Su-Xia Wang; Feng Yu; Ming-Hui Zhao
Journal:  Pediatr Nephrol       Date:  2018-10-12       Impact factor: 3.714

6.  Effect of Type 2 Diabetes Mellitus and Diabetic Nephropathy on IgG Pharmacokinetics and Subcutaneous Bioavailability in the Rat.

Authors:  Gurkishan S Chadha; Marilyn E Morris
Journal:  AAPS J       Date:  2015-04-30       Impact factor: 4.009

7.  Regulation of human IgG subclass production by cytokines: human IgG subclass production enhanced differentially by interleukin-6.

Authors:  Y Kawano; T Noma; K Kou; I Yoshizawa; J Yata
Journal:  Immunology       Date:  1995-02       Impact factor: 7.397

8.  A mouse monoclonal antibody against dengue virus type 1 Mochizuki strain targeting envelope protein domain II and displaying strongly neutralizing but not enhancing activity.

Authors:  Atsushi Yamanaka; Tomohiro Kotaki; Eiji Konishi
Journal:  J Virol       Date:  2013-09-18       Impact factor: 5.103

9.  IgG2 subclass restriction of anti-beta 2 glycoprotein 1 antibodies in autoimmune patients.

Authors:  J Arvieux; B Roussel; D Ponard; M G Colomb
Journal:  Clin Exp Immunol       Date:  1994-02       Impact factor: 4.330

10.  Gamma heavy chain disease in a patient with diabetes and chronic renal insufficiency: diagnostic assessment of the heavy chain fragment.

Authors:  Maria Teresa Lee; Anil Parwani; Richard Humphrey; Robert G Hamilton; Donna I Myers; Barbara Detrick
Journal:  J Clin Lab Anal       Date:  2008       Impact factor: 2.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.